Darwin Global Management Ltd. Buys 2,463,261 Shares of Insmed Incorporated (NASDAQ:INSM)

Darwin Global Management Ltd. raised its position in Insmed Incorporated (NASDAQ:INSM - Free Report) by 23.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,960,538 shares of the biopharmaceutical company's stock after purchasing an additional 2,463,261 shares during the quarter. Insmed accounts for about 84.8% of Darwin Global Management Ltd.'s holdings, making the stock its biggest holding. Darwin Global Management Ltd. owned about 7.24% of Insmed worth $894,796,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC boosted its stake in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 163 shares in the last quarter. V Square Quantitative Management LLC increased its position in shares of Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 248 shares during the last quarter. Spire Wealth Management purchased a new position in Insmed in the fourth quarter valued at about $47,000. Smartleaf Asset Management LLC grew its stake in shares of Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 411 shares during the period. Finally, Venturi Wealth Management LLC purchased a new position in Insmed in the 4th quarter valued at approximately $86,000.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on INSM shares. Truist Financial boosted their target price on Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Stifel Nicolaus lowered their target price on Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research note on Friday, February 21st. JPMorgan Chase & Co. increased their price target on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research note on Friday, February 7th. Wells Fargo & Company lifted their price objective on Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a research note on Wednesday, February 19th. Finally, UBS Group increased their price target on shares of Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a report on Thursday, March 6th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $94.00.

Insider Buying and Selling

In other news, COO Roger Adsett sold 42,975 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $78.61, for a total transaction of $3,378,264.75. Following the transaction, the chief operating officer now directly owns 146,082 shares of the company's stock, valued at approximately $11,483,506.02. This trade represents a 22.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO William Lewis sold 6,830 shares of the company's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $72.57, for a total transaction of $495,653.10. Following the completion of the sale, the chief executive officer now directly owns 233,924 shares of the company's stock, valued at approximately $16,975,864.68. This trade represents a 2.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 387,487 shares of company stock worth $30,825,692. Corporate insiders own 3.00% of the company's stock.

Insmed Stock Performance

INSM traded down $0.34 during midday trading on Friday, reaching $72.30. The company had a trading volume of 1,600,638 shares, compared to its average volume of 2,309,882. The business has a 50-day moving average of $73.53 and a two-hundred day moving average of $73.50. The company has a market cap of $13.15 billion, a P/E ratio of -12.93 and a beta of 1.07. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The business had revenue of $104.44 million during the quarter, compared to analysts' expectations of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. As a group, equities research analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.